AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04996017
Drug: Atezolizumab 1200 mg in 20 ML Injection
RxNorm normalized name: atezolizumab 1200 MG in 20 ML Injection
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Atezolizumab will be supplied as sterile liquid in 20-mL glass vials. The vial is designed to deliver 20 mL (1200 mg) of atezolizumab solution but may contain more than the stated volume to enable delivery of the entire 20 mL volume. For information on the formulation and handling of atezolizumab, refer to the Atezolizumab Investigator's Brochure.
Trial: NCT06447987
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04886284
Drug: Ertapenem
RxNorm normalized name: Ertapenem
DrugBank: Ertapenem (DB00303)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Adjunctive ertapenem
Trial: NCT05979727
Drug: RE02
RxNorm normalized name: Ropinirole
DrugBank: Ropinirole (DB00268)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low, medium or high dose of RE02
Trial: NCT05979727
Drug: Manitol
RxNorm normalized name: Manitol
DrugBank: Mannitol (DB00742)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo Comparator
Trial: NCT05314764
Drug: Cefiderocol
RxNorm normalized name: Cefiderocol
DrugBank: Cefiderocol (DB14879)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients will receive intravenous cefiderocol every 6 to 8 hours for 4 to 6 doses.
Trial: NCT06602063
Drug: Sintilimab
RxNorm normalized name: Sintilimab
DrugBank: Sintilimab (DB15765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sintilimab will be administered at a fixed dose of 200 mg IV every 21 days. Treatment will continue until disease progression confirmed by RECIST criteria v1.1, intolerable toxicity or withdrawal of consent.
Trial: NCT05324332
Drug: 68Ga-P16-093
RxNorm normalized name: 68Ga-DOTATOC
DrugBank: Dotatate gallium Ga-68 (DB13925)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 68Ga-P16-093 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-P16-093 will be used to image lesions of prostate cancer by PET/CT.
Trial: NCT05370820
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV 2 minutes, IV 10 minutes, IM
Trial: NCT05281562
Drug: Lovaza
RxNorm normalized name: Lovaza
DrugBank: Omega-3-acid ethyl esters (DB09539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of 1.68grams omega-3 fatty acids, 2 Lovaza pills per day.
Trial: NCT05324332
Drug: 68Ga-PSMA-11
RxNorm normalized name: 68Ga-Psma-11
DrugBank: Gallium Ga-68 gozetotide (DB16019)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous injection of 68Ga-PSMA-11 with the dosage of 1.8-2.2 MBq (0.05-0.06 mCi)/kg. Tracer doses of 68Ga-PSMA-11 will be used to image lesions of prostate cancer by PET/CT.
Trial: NCT05281562
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily dose of 500 mg Vitamin C, powder form.
Trial: NCT06589830
Drug: Trastuzumab
RxNorm normalized name: trastuzumab
DrugBank: Trastuzumab (DB00072)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous (IV) infusion
Trial: NCT06002490
Drug: P1101
RxNorm normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The subjects will be treated with P1101(ropeginterferon alfa-2b), starting at a dose of 250 micrograms. The dose of P1101 will be increased to 350 micrograms 2 weeks later and to 500 micrograms another 2 weeks later, and then P1101 will be administered at a fixed dose of 500 micrograms throughout the treatment period. Although the dose may be reduced to the prior dose for reasons related to the safety or tolerability, the increased dose should be preferably maintained throughout the treatment period.~The dose of P1101 will be increased or decreased appropriately depending on the pathological condition in the range up to 500 micrograms.
Trial: NCT06002490
Drug: Low-dose aspirin
RxNorm normalized name: low-dose aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low-dose aspirin (acetylsalicylic acid) (75-150 mg/day) will be given as background therapy during the 12 months of study treatment, unless contraindicated.
Trial: NCT06331026
Drug: PEG-rhGH with new preparation (T)
RxNorm normalized name: RhGH-PEG
DrugBank: Lonapegsomatropin (DB16220)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: A single subcutaneous injection of PEG-rhGH with new preparation
Trial: NCT06331026
Drug: PEG-rhGH with present preparation (R)
RxNorm normalized name: cranberry preparation
DrugBank: Cranberry (DB10631)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A single subcutaneous injection of PEG-rhGH with present preparation
Trial: NCT06484491
Drug: Cisplatin or carboplatin + pemetrexed for induction chemotherapy, cisplatin + docetaxel for concurrent chemotherapy
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Induction course:~-Cisplatin (75 mg/m2) or carboplatin (AUC 6) + pemetrexed (500mg/m2).~Concurrent chemoradiotherapy:~* Weekly cisplatin (20mg/m2) + docetaxel (20mg/m2) on Mondays.~* Radiotherapy will be given for 5x5 days.
Trial: NCT06484491
Drug: Immunotherapy: adjuvant durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Adjuvant treatment will be given starting 1-6 weeks after chemoradiotherapy if no progression, good performance (PS 0-1), no other contra-indication for immunotherapy.~Doses:~* Start durvalumab 10 mg/kg 1x/14 days.~* If possible after 2 courses switch to 1500 mg flat dose 1x/4 wk.~* Continue for 12 months in total.
Trial: NCT05852262
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg PO QID for 7 days
Trial: NCT05852262
Drug: Cephalexin
RxNorm normalized name: Cephalexin
DrugBank: Cephalexin (DB00567)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg PO QID plus oral placebo for 7 days
Trial: NCT04732169
Drug: Active study drug ( oral CBD)
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CBD in single dose syringes
Trial: NCT00110903
Drug: Etanercept Liquid
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04705909
Drug: Pitavastatin
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin 2 mg oral tablets daily will be given to the patients concomitantly with the intended chemotherapy protocol for the treatment period prior to surgery.
Trial: NCT06556641
Drug: Insulin Degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Administered as once daily subcutaneous dose
Trial: NCT04986579
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT04986579
Drug: Sacituzumab govitecan
RxNorm normalized name: sacituzumab govitecan
DrugBank: Sacituzumab govitecan (DB12893)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intravenous Infusion
Trial: NCT04986579
Drug: Trastuzumab deruxtecan
RxNorm normalized name: Trastuzumab deruxtecan
DrugBank: Trastuzumab deruxtecan (DB14962)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Intravenous Infusion
Trial: NCT05672121
Drug: KH631
RxNorm normalized name: Ketamine hydrochloride
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: KH631: AAV vector containing a coding sequence for an anti-VEGF protein
Trial: NCT06481826
Drug: Glofitamab
RxNorm normalized name: Glofitamab
DrugBank: Glofitamab (DB16371)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glofitamab given in standard dosage
Trial: NCT05030857
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: On Days 1, 3 and 13, participants will receive a single oral dose of MDZ as an oral solution in fasted state.
Trial: NCT05386576
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: During Induction I, for patients on Dose Level 1, venetoclax will be administered at a dose of 100mg on day 5, 200mg on day 6 and 400mg on days 7-28. For patients on Dose Level 01, venetoclax will be administered at a dose of 100mg on day 5 and 200mg on days 6-28.~During Induction II, venetoclax will be administered at either 400mg daily (Dose Level 1) or 200mg daily (Dose Level -1) from days 1-14 and 29-42.
Trial: NCT06010732
Drug: 1100 ppm F as sodium fluoride (positive control)
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.
Trial: NCT06010732
Drug: 1100 ppm F as sodium fluoride Test Product
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: • Each subject will use this product during one of the three treatment periods in the crossover study design.
Trial: NCT04789681
Drug: Canakinumab
RxNorm normalized name: Canakinumab
DrugBank: Canakinumab (DB06168)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Given SC
Trial: NCT04662580
Drug: Apalutamide
RxNorm normalized name: Apalutamide
DrugBank: Apalutamide (DB11901)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral tablet and will be given once daily by mouth.
Trial: NCT04662580
Drug: Abiraterone acetate
RxNorm normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral tablet and will be given once daily by mouth.
Trial: NCT04662580
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral tablet and will be given once daily in metastatic castration-sensitive prostate cancer( mCSPC) and twice daily in metastatic castration-resistant prostate cancer (mCRPC) cohort by mouth.
Trial: NCT05621551
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: The patients is required to receive dapagliflozin(10mg, q.d.) at least for 3 days until 24 hours before the surgery. Then dapagliflozin will be discontinued and recovered as soon as the patient is able to take oral diet postoperatively. Dapagliflozin wil be ceased five days after surgery.
Trial: NCT06251973
Drug: Balstilimab
RxNorm normalized name: Balstilimab
DrugBank: Balstilimab (DB15676)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Botensilimab is supplied as a sterile, single-use solution for IV administration
Trial: NCT06251973
Drug: Ramucirumab
RxNorm normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ramucirumab is a fully human anti-VEGFR2 monoclonal IgG1 antibody (IgG1) that binds with high affinity to the extracellular domain of VEGFR2. Ramucirumab is a part of standard of care treatment for advanced gastric cancer or GEJ adenocarcinoma, after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
Trial: NCT06251973
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel is widely used across multiple cancer types and is a part of standard of care treatment for advanced EG adenocarcinoma after prior treatment with fluoropyrimidine- or platinum-containing chemotherarapy.
Trial: NCT04706910
Drug: 18F-DOPA
RxNorm normalized name: (-)-dopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All participants will receive an intravenous injection of 18F-DOPA (4MBq/kg; minimum 110 MBq, maximum 600 MBq) for this study
Trial: NCT04706910
Drug: Furosemide Injection
RxNorm normalized name: furosemide Injection
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Some participants will receive an intravenous injection of furosemide (40mg, single dose)
Trial: NCT05357794
Drug: Brentuximab vedotin
RxNorm normalized name: Brentuximab Vedotin
DrugBank: Brentuximab vedotin (DB08870)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given by Vein (IV)
Trial: NCT05239728
Drug: Belzutifan
RxNorm normalized name: BELZUTIFAN
DrugBank: Belzutifan (DB15463)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Three 40 mg tablets given as a single oral 120 mg dose.
Trial: NCT06526117
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The study intervention will include initial treatment with low-dose hydroxyurea therapy at 10 mg/kg/day (range 7 - 15 mg/kg/day), with subsequent increase to moderate dose hydroxyurea therapy at 20 mg/kg/day (range 17.5 - 26 mg/kg/day) after at least two severe events requiring physician contact.
Trial: NCT05573126
Drug: Elacestrant
RxNorm normalized name: Elacestrant
DrugBank: Elacestrant (DB06374)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral SERD
Trial: NCT05573126
Drug: Everolimus
RxNorm normalized name: Everolimus
DrugBank: Everolimus (DB01590)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: mTOR Inhibitor
Trial: NCT06480630
Drug: Basiliximab
RxNorm normalized name: Basiliximab
DrugBank: Basiliximab (DB00074)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Addition of CD25 monoclonal antibody（Basiliximab） at +3 days post unrelated umbilical cord blood transplantation (UCBT)
Trial: NCT05614739
Drug: LOXO-435
RxNorm normalized name: Loxoprofene
DrugBank: Loxoprofen (DB09212)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Oral
Trial: NCT05614739
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: IV
Trial: NCT05664750
Drug: TNM002
DrugBank: M002 (DB18318)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosage Form: Injection, solution~Route of administration: IM gluteal injection
Trial: NCT05511519
Drug: ATI-450
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, small molecule MK2 inhibitor
Trial: NCT05668871
Drug: Danning Tablet
RxNorm normalized name: chlorpheniramine tannate Oral Tablet [Ed Chlor Tan]
DrugBank: Chlorpheniramine (DB01114)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times each day, 5 tablets each time, take orally after meals.
Trial: NCT04216290
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT04216290
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04216290
Drug: Mitomycin
RxNorm normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06066528
Drug: Survodutide
RxNorm normalized name: Survodutide
DrugBank: Survodutide (DB18989)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once weekly subcutaneous injection
Trial: NCT05260021
Drug: Tirzepatide Dose 1
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT05260021
Drug: Tirzepatide Dose 2
RxNorm normalized name: Tirzepatide
DrugBank: Tirzepatide (DB15171)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT06466187
Drug: PF-08052666
RxNorm normalized name: PF-05089771
DrugBank: PF-05089771 (DB14856)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given into the vein (IV; intravenously)
Trial: NCT06107504
Drug: Sucralfate
RxNorm normalized name: Sucralfate
DrugBank: Sucralfate (DB00364)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2g of sucralfate powder and 1g of tranexamic acid powder will be sprayed after EST
Trial: NCT06005168
Drug: Cefazolin for Injection
RxNorm normalized name: Cefazolin for Injection
DrugBank: Cefazolin (DB01327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 grams or 3 grams based on standard of care or morphomic-based decision
Trial: NCT05523297
Drug: Octaplex
DrugBank: Prothrombin (DB11311)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prothrombin complex concentrate
Trial: NCT00001122
Drug: Nelfinavir mesylate
RxNorm normalized name: Nelfinavir Mesylate
DrugBank: Nelfinavir (DB00220)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001122
Drug: Efavirenz
RxNorm normalized name: Efavirenz
DrugBank: Efavirenz (DB00625)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001122
Drug: Stavudine
RxNorm normalized name: Stavudine
DrugBank: Stavudine (DB00649)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00001122
Drug: Didanosine
RxNorm normalized name: Didanosine
DrugBank: Didanosine (DB00900)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06319118
Drug: dihydroergotine mesylate sustained-release tablets
RxNorm normalized name: Dihydroergotamine Mesylate
DrugBank: Dihydroergotamine (DB00320)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dihydroergotine mesylate extended-release tablets + conventional treatment, dihydroergotine mesylate sustained-release tablets 5mg daily; 2.5mg 2 times daily, after breakfast and dinner.
Trial: NCT06159777
Drug: Polyethylene Glycol 3350
RxNorm normalized name: Polyethylene Glycol 3350
DrugBank: Polyethylene glycol (DB09287)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \*Polyethylene glycol 3350 (PEG) will be used within it's FDA indication and dosing for constipation. Each 17-gram dose of PEG is to be mixed in 8oz of liquid.
Trial: NCT05211323
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT06304870
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient lies supine without a pillow, turns the head to the contralateral side of the block, and at the midpoint of the line connecting the angle of the mandible with the mastoid process (the styloid process), the skin is disinfected, and a 22-gauge, 3.8 cm puncture needle is loaded onto a 5 mL syringe. The puncture needle is inserted perpendicularly to the skin surface at the styloid process, and advanced through the skin and subcutaneous tissue until it contacts the bone of the styloid process. The puncture needle is then retracted and advanced anteriorly beyond the styloid process by 0.5-1.0 cm. When no blood or cerebrospinal fluid is aspirated, the blocking drug can be injected \[20 g/L lidocaine injection\].
Trial: NCT04718961
Drug: Volixibat
RxNorm normalized name: Volixibat
DrugBank: Volixibat (DB13914)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral capsules, administered twice daily. Volixibat is an ileal bile acid transporter (IBAT) inhibitor.
Trial: NCT06528431
Drug: Step Wedge trial
RxNorm normalized name: PostDay One-Step
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Step Wedge trial : At baseline, all the patients will receive in this study the standard adalimumab dosing regimen. At subsequent time points (steps), patients will begin the intervention of interest, here the tapering adalimumab strategy. The time at which a patient begins the intervention will be randomized. We fixed the time steps duration to 3 months that corresponds the frequency of there commended follow-up of RA patients
Trial: NCT05753618
Drug: Granulocyte Colony-Stimulating Factor (G-CSF)
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Participants will receive G-CSF injection (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy.
Trial: NCT05753618
Drug: Omission of Granulocyte Colony-Stimulating Factor (G-CSF)
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will omit the use of G-CSF (either filgrastim or pegfilgrastim) after each paclitaxel cycle of DD-AC/T chemotherapy
Trial: NCT06557174
Drug: IMC-002
RxNorm normalized name: IMC-18F1
DrugBank: Icrucumab (DB14824)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous injection: Weekly administered for a period of first 4 weeks, then rest for 20 weeks. After the administration of the testing drug, if the subject's symptoms get worsen, a rescue therapy need to be adopted as based on Investigator's judgement, the testing drug injection should be discontinued.
Trial: NCT04627025
Drug: apraglutide
RxNorm normalized name: Apraglutide
DrugBank: Apraglutide (DB18084)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apraglutide is a peptide analogue of GLP-2 under development for treatment of SBS-IF, which acts as a full agonist at the GLP-2 receptor with in vitro potency and selectivity comparable with native GLP-2.
Trial: NCT06537518
Drug: Dexamethasone injection
RxNorm normalized name: dexamethasone Injection
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone, a potent glucocorticoid, decreases the inflammatory response, tissue damage, and pain after surgical procedures; which can be injected locally or Intravenously.
Trial: NCT06537518
Drug: Bupivacaine 0.375% Injectable Solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Isobaric bupivacaine (0.375%) is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
Trial: NCT06537518
Drug: Bupivacaine 0.5% Injectable Solution
RxNorm normalized name: BUPivacaine 0.5% injectable solution
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 ml of Bupivacain 0.5% was mixed with dexamethasone 8 mg is injected into the adductor canal deeply to the sartorius muscle around the saphenous nerve after ensuring negative aspiration space.
Trial: NCT06477133
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pre-mixed solution of 2 grams of magnesium sulfate dissolved in 20 mL sterile water
Trial: NCT05211323
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV